<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathogenesis of paroxysmal nocturnal hemoglobinuria</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathogenesis of paroxysmal nocturnal hemoglobinuria</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathogenesis of paroxysmal nocturnal hemoglobinuria</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert A Brodsky, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disorder in which hematopoietic stem cells and their cellular progeny have reduced or absent glycosylphosphatidylinositol (GPI)-anchored proteins on the cell surface. Loss of the GPI-linked complement inhibitors, CD55 and CD59, on red blood cells (RBCs) leads to chronic and/or paroxysmal intravascular hemolysis and a propensity for thrombosis, organ dysfunction, and hypocellular or dysplastic bone marrow. A subset of patients with PNH have clinically significant aplastic anemia or myelodysplastic syndrome.</p><p>PNH was one of the first hematologic disorders with a clear clinical description; the defining symptom, dark urine at night, was distinctive and easily observed. Subsequent investigations have clarified much of the pathogenesis of the disease, including the genetic defect and the mechanism of complement-mediated hemolysis. </p><p>This topic discusses the pathogenesis of PNH. </p><p>The clinical manifestations, diagnosis, and treatment of PNH are presented in detail separately. (See  <a class="medical medical_review" href="/d/html/7159.html" rel="external">"Clinical manifestations and diagnosis of paroxysmal nocturnal hemoglobinuria"</a> and  <a class="medical medical_review" href="/d/html/7163.html" rel="external">"Treatment and prognosis of paroxysmal nocturnal hemoglobinuria"</a>.)</p><p class="headingAnchor" id="H24327698"><span class="h1">PNH STEM CELL</span><span class="headingEndMark"> — </span>PNH originates from an acquired genetic defect (mutation) in a multipotent hematopoietic stem cell, or in a hematopoietic progenitor cell that acquires stem cell properties and is able to survive, expand, and self-renew. PNH can arise de novo or in the setting of an underlying bone marrow disorder such as aplastic anemia (AA), myelodysplastic syndrome (MDS), or primary myelofibrosis (PMF) [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H24327574"><span class="h2"><i>PIGA</i> gene mutation</span><span class="headingEndMark"> — </span>The acquired mutation in PNH occurs in the <em>PIGA</em> gene (<strong>p</strong>hosphatidyl<strong>i</strong>nositol <strong>g</strong>lycan anchor biosynthesis, class <strong>A</strong>; <em>PIG-A</em>; MIM311770), which is responsible for the first step in the synthesis of the glycosylphosphatidylinositol (GPI) anchor that attaches a subset of proteins to the cell surface  (<a class="graphic graphic_figure graphicRef96559" href="/d/graphic/96559.html" rel="external">figure 1</a>) [<a href="#rid2">2</a>]. </p><p>The <em>PIGA</em> gene is located on the X chromosome. Therefore, a single "hit" (ie, a mutation in only one allele of the gene) will generate a PNH phenotype because males have only one X chromosome and females undergo X chromosome inactivation (lyonization) in every somatic cell, including hematopoietic stem cells [<a href="#rid2">2</a>]. </p><p>A large spectrum of acquired <em>PIGA</em> mutations has been described [<a href="#rid3">3-13</a>]. The majority involve a frame-shift that creates a premature stop codon, resulting in a truncated protein product that is unstable and rapidly degraded. With few exceptions, mutations are unique to a patient, suggesting the absence of a mutational hot spot within the gene.</p><p>The mechanism of <em>PIGA</em> mutation is unknown. Mutagenic events such as exposure to excessive radiation, administration of mutagenic chemotherapy, or underlying defects in DNA repair are seldom seen in individuals with PNH. The close association between PNH and acquired AA (an autoimmune disease) suggests that the immune attack on hematopoietic stem cells provides a conditional survival advantage to the PNH clone. (See <a class="local">'Clonal selection and expansion'</a> below.)</p><p>Interestingly, many individuals, including healthy blood donors, have rare circulating blood cells with a <em>PIGA</em> mutation [<a href="#rid14">14</a>]. However, in contrast to patients with PNH and those with AA and a small PNH clone, in healthy individuals the <em>PIGA</em> mutations arise in hematopoietic precursor cells that lack the capacity for self-renewal, rather than in hematopoietic stem cells [<a href="#rid15">15,16</a>].</p><p>Germline <em>PIGA</em> null mutations are lethal during embryogenesis [<a href="#rid17">17,18</a>]. However, inherited <em>PIGA</em> mutations that lead to partial PIGA expression (hypomorphs) cause a syndrome known as <strong>m</strong>ultiple <strong>c</strong>ongenital <strong>a</strong>nomalies-<strong>h</strong>ypotonia-<strong>s</strong>eizure syndrome 2 (MCAHS2, MIM300818) [<a href="#rid19">19,20</a>]. Children with MCAHS2 present with severe intellectual disability, dysmorphic facial features, and seizures, and they have a markedly shortened lifespan. In MCAHS2, the GPI anchor protein deficiency is most conspicuous on granulocytes. Red blood cells (RBCs) from these patients have little to no GPI anchor deficiency and no hemolysis. (See <a class="local">'GPI anchor'</a> below.)</p><p class="headingAnchor" id="H24329534"><span class="h2">Other initiating mutations</span><span class="headingEndMark"> — </span>Lack of the complement inhibitor CD59 on the RBC surface is mostly responsible for the clinical manifestations in PNH. Rare cases of inherited mutations in <em>CD59</em> leading to loss of CD59 on the RBC surface have been well documented. These patients manifest with chronic intravascular hemolysis, paroxysmal flares of hemolysis, and a propensity for thrombosis. Unlike patients with PNH due to <em>PIGA</em> mutations, those with inherited CD59 deficiency also have relapsing immune-mediated peripheral neuropathy [<a href="#rid21">21</a>]. In the classical form of PNH, the CD59 deficiency is only found on blood cells; in patients with germline <em>CD59</em> mutations, CD59 is deficient in all cells in the body. </p><p>An alternative genetic defect (<em>PIGT</em>) leading to GPI deficiency and PNH symptoms has been reported in which there is complete loss of <em>PIGT</em> due to the combination of a germline mutation in one allele and a somatic mutation affecting the other allele on chromosome 20q [<a href="#rid22">22</a>]. </p><p class="headingAnchor" id="H24327581"><span class="h2">Clonal selection and expansion</span><span class="headingEndMark"> — </span>For PNH to manifest clinically, the hematopoietic stem cell carrying a <em>PIGA</em> mutation must undergo clonal expansion. (See <a class="local">'Progression to pancytopenia/aplastic anemia'</a> below.)</p><p>Various mechanisms have been described for expansion of the PNH clone:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune escape</strong> – <em>PIGA</em> mutations do not offer a selective advantage, but they do protect cells from immune mediated destruction, as occurs in AA. Thus, expansion of a PNH clone requires both <em>PIGA</em> mutation and growth suppression of unaffected hematopoietic cells. This is supported by finding of PNH in patients with other underlying bone marrow disorders that impair hematopoiesis (eg, MDS, AA) [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selective advantage for clonal expansion</strong> – Acquisition of additional mutation(s) or other modifications may provide a selective advantage, either due to accelerated proliferation or reduced apoptosis (programmed cell death); however, the mutation rate in PNH cells is similar to that of non-PNH cells [<a href="#rid24">24-27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neutral evolution</strong> – In "neutral evolution," PNH clones do not have a survival advantage, but one or more clones expand stochastically during periods of bone marrow regeneration. Neutral evolution is supported by several lines of evidence including mathematical modeling simulations of hematopoietic stem cell evolution; the finding of PNH mutations in a large number of unaffected blood donors; and the occasional finding of clonal extinction and spontaneous remission of PNH [<a href="#rid14">14,17,24</a>].</p><p></p><p class="headingAnchor" id="H87613010"><span class="h2">Progression to pancytopenia/aplastic anemia</span><span class="headingEndMark"> — </span>Acquired AA and PNH are closely related diseases. Small clonal populations of PNH cells can be found in up to 65 percent of patients with newly diagnosed AA, and many patients with de novo PNH have some degree of underlying bone marrow failure.</p><p>The management of pancytopenia in PNH, including the role of immunosuppressive therapies and hematopoietic stem cell transplantation, is presented separately. (See  <a class="medical medical_review" href="/d/html/7163.html" rel="external">"Treatment and prognosis of paroxysmal nocturnal hemoglobinuria"</a>.)</p><p class="headingAnchor" id="H24327758"><span class="h1">GPI ANCHOR</span></p><p class="headingAnchor" id="H3607533"><span class="h2">Molecular structure</span><span class="headingEndMark"> — </span>The PIGA protein is involved in the synthesis of the glycosylphosphatidylinositol (GPI) anchor, a glycolipid that links dozens of cell-surface proteins to the plasma membrane on hematopoietic cells, including blood group antigens, adhesion molecules, and complement regulatory proteins  (<a class="graphic graphic_figure graphicRef96559" href="/d/graphic/96559.html" rel="external">figure 1</a>) [<a href="#rid2">2</a>]. The significance for hematopoietic cell function is known for some, but not all, of these proteins.</p><p>GPI is a large molecule synthesized in the endoplasmic reticulum; over 25 genes and at least 10 biochemical reactions are involved in its synthesis [<a href="#rid28">28</a>]. Once formed, the intact GPI anchor is transferred to the carboxyl terminus of proteins that have a GPI-attachment signal peptide, and the GPI-linked protein is then transported to the plasma membrane, where it is retained in microdomains known as lipid rafts.</p><p>The GPI anchor consists of a molecule of phosphatidylinositol (PI), a glycan core containing a molecule of N-glucosamine and three molecules of mannose, and a molecule of ethanolamine [<a href="#rid29">29</a>]. On the cell surface, the PI end of the anchor is inserted into the lipid bilayer of the plasma membrane and the ethanolamine end is attached by an amide bond to the carboxyl end of a protein molecule. The PIGA protein is involved in the first step in GPI biosynthesis, in which N-acetylglucosamine is transferred to phosphatidylinositol to form GlcNAc-PI.</p><p class="headingAnchor" id="H87616365"><span class="h2">Cellular effects</span><span class="headingEndMark"> — </span>The best-described and most clinically significant consequence of reduced GPI-anchored proteins pertaining to PNH is increased complement-mediated hemolysis. (See <a class="local">'Complement-mediated hemolysis'</a> below.)</p><p>Separate populations of RBCs have been defined according to the abundance of GPI-anchored proteins on the cell surface: </p><p class="bulletIndent1"><span class="glyph">●</span>PNH type I cells – Normal levels</p><p class="bulletIndent1"><span class="glyph">●</span>PNH type II cells – Partial absence</p><p class="bulletIndent1"><span class="glyph">●</span>PNH III cells – Complete absence</p><p></p><p>Cells of partial GPI deficiency (PNH type II cells) are found in approximately half of patients with PNH examined. In some patients, they appear to represent a distinct population of cells; in others, they seem to be "transitional" between the cells bearing normal amounts of protein and those bearing none. In some cases, a missense mutation in the <em>PIGA</em> gene, which changes the amino acid sequence of the protein, causes limited production of the protein or a protein with diminished activity. Thus, in patients with both PNH type II and PNH type III cells, each population may be derived from a separate PNH clone. (See <a class="local">'PIGA gene mutation'</a> above.)</p><p>In almost all patients with PNH, cells completely lacking in GPI-linked proteins (PNH type III cells) may be found as a discrete population. These cells are the most sensitive to complement-mediated lysis and the most readily lysed in vivo. The proportion of these cells varies; they can be depleted by a recent hemolytic crisis or diluted by a recent blood transfusion.</p><p class="headingAnchor" id="H87618385"><span class="h1">ANEMIA</span><span class="headingEndMark"> — </span>Anemia in PNH is often multifactorial and may result from a combination of red blood cell (RBC) destruction (hemolysis) and lack of production due to underlying bone marrow failure, iron deficiency, or other bone marrow insults [<a href="#rid30">30</a>]. Hemolysis is the major mechanism in patients with classical PNH. (See  <a class="medical medical_review" href="/d/html/7159.html" rel="external">"Clinical manifestations and diagnosis of paroxysmal nocturnal hemoglobinuria", section on 'Diagnostic criteria'</a>.)</p><p>Repeated episodes of hemolysis can also lead to iron deficiency as scavenged iron is shed in renal tubular epithelial cells. </p><p>PNH may also be diagnosed in the context of aplastic anemia (ie, PNH/aplastic anemia overlap). These patients tend to have pancytopenia, a low reticulocyte count and a hypocellular bone marrow. (See  <a class="medical medical_review" href="/d/html/7159.html" rel="external">"Clinical manifestations and diagnosis of paroxysmal nocturnal hemoglobinuria", section on 'PNH with bone marrow failure'</a>.)</p><p class="headingAnchor" id="H24327588"><span class="h2">Complement-mediated hemolysis</span><span class="headingEndMark"> — </span>Complement-mediated intravascular hemolysis is the most prominent clinical feature in classical PNH. Evidence of intravascular hemolysis includes the presence of free hemoglobin in the serum or urine, decreased serum haptoglobin, and elevated serum lactate dehydrogenase (LDH). Elevation of LDH to &gt;1.5 times the upper limit of normal can be seen with as few as 3 percent PNH RBCs [<a href="#rid31">31</a>]. Hemolysis in PNH is not exclusively nocturnal and may be seen continuously by sensitive methods including the serum haptoglobin and LDH.</p><p>Clinically significant anemia in untreated patients with PNH is largely due to intravascular hemolysis; however, both intravascular and extravascular hemolysis occur. These are both mediated by complement-dependent RBC lysis rather than an antibody/autoimmune mechanism. Thus, untreated patients with PNH have a Coombs-negative hemolytic anemia. (See  <a class="medical medical_review" href="/d/html/7076.html" rel="external">"Diagnosis of hemolytic anemia in adults"</a>.) </p><p>RBCs in individuals <strong>without </strong>PNH are protected from complement lysis by GPI-anchored proteins on their surface that block complement activation  (<a class="graphic graphic_figure graphicRef96560" href="/d/graphic/96560.html" rel="external">figure 2</a>). Intravascular hemolysis is blocked by CD59, and extravascular hemolysis by CD55. (See <a class="local">'Intravascular hemolysis from reduced CD59'</a> below and <a class="local">'Extravascular hemolysis from reduced CD55'</a> below and  <a class="medical medical_review" href="/d/html/3967.html" rel="external">"Regulators and receptors of the complement system"</a>.)</p><p>Hemolysis occurs in individuals with PNH because these complement inhibitors are missing. In the absence of these inhibitors, complement proteins that bind mammalian cell membranes (self) through the alternative complement pathway can lyse self-cells as if they were bacteria  (<a class="graphic graphic_figure graphicRef59641" href="/d/graphic/59641.html" rel="external">figure 3</a>). (See  <a class="medical medical_review" href="/d/html/3968.html" rel="external">"Complement pathways"</a>.) </p><p>The degree of hemolysis depends on several factors, including the number of GPI-deficient cells, the degree of GPI deficiency, and the presence of additional precipitating events. Examples of precipitating factors include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Administration of iron to an iron-deficient patient is thought to result in delivery of a large number of complement-sensitive cells to the circulation [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exposure to microorganisms (viruses or bacteria) is thought to increase complement activation, especially in the gastrointestinal tract. Nocturnal hemolysis has been attributed to the intestinal absorption of lipopolysaccharide, a potent complement activator [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A surgical procedure may precipitate complement activation via inflammatory mediators. </p><p></p><p>Importantly, patients with PNH treated with <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> (a monoclonal antibody that blocks terminal complement) often develop a Coombs-positive hemolytic anemia that is C3-positive, IgG-negative, because eculizumab prevents the membrane attack complex from forming on the PNH red cells and prevents intravascular hemolysis  (<a class="graphic graphic_figure graphicRef96560" href="/d/graphic/96560.html" rel="external">figure 2</a>).</p><p class="headingAnchor" id="H24329547"><span class="h3">Intravascular hemolysis from reduced CD59</span><span class="headingEndMark"> — </span>The major mechanism of hemolysis in PNH is complement-dependent intravascular hemolysis (ie, hemolysis of RBCs in the circulation) [<a href="#rid2">2</a>]. Intravascular hemolysis is normally blocked by CD59 (also called membrane inhibitor of reactive lysis [MIRL], protectin, homologous restriction factor, and membrane attack complex inhibitory factor [MACIF]), which prevents the final stage of complement assembly, production of the membrane attack complex [MAC] that forms a pore in the target cell  (<a class="graphic graphic_figure graphicRef59641" href="/d/graphic/59641.html" rel="external">figure 3</a>) [<a href="#rid34">34</a>]. Intravascular hemolysis occurs in PNH because RBCs lack the GPI anchor required to attach CD59 to their surface [<a href="#rid28">28,34-51</a>].</p><p>Intravascular hemolysis leads to release of free hemoglobin into the blood. Free hemoglobin in turn can cause various toxic effects, including hypercoagulability, changes in vascular tone from reduction of circulating nitric oxide, and renal damage. (See <a class="local">'Thrombosis'</a> below and <a class="local">'Smooth muscle dystonia'</a> below and  <a class="medical medical_review" href="/d/html/14034.html" rel="external">"Clinical features and diagnosis of heme pigment-induced acute kidney injury"</a>.)</p><p>Free hemoglobin is detected in laboratory testing by observation of pink/red serum or urine, and measurement of reduced haptoglobin, increased LDH, and increased reticulocyte count in iron-replete individuals. Urinalysis will show a positive dipstick for heme but no red blood cells in the sediment. (See  <a class="medical medical_review" href="/d/html/7159.html" rel="external">"Clinical manifestations and diagnosis of paroxysmal nocturnal hemoglobinuria", section on 'Hemolysis'</a>.)</p><p class="headingAnchor" id="H24329553"><span class="h3">Extravascular hemolysis from reduced CD55</span><span class="headingEndMark"> — </span>Extravascular hemolysis also occurs in PNH, due to complement-mediated destruction of RBCs by reticuloendothelial macrophages in the liver and spleen. Extravascular hemolysis is normally blocked by CD55 (also called decay accelerating factor [DAF]), which prevents assembly of the C3 and C5 convertases upstream of MAC formation in the complement cascade. CD55 is normally attached to the RBC surface via a GPI anchor [<a href="#rid52">52-56</a>]. CD55 protects RBCs from hemolysis by inhibiting C3 convertases such as the C4b2a complex, which enzymatically cleaves and activates C3 [<a href="#rid28">28,57</a>]. Accumulation of C3 on the RBC surface in the absence of CD55 identifies (opsonizes) RBCs for reticuloendothelial destruction. (See  <a class="medical medical_review" href="/d/html/3967.html" rel="external">"Regulators and receptors of the complement system"</a>.)</p><p>Extravascular hemolysis can persist in individuals treated with the monoclonal antibody <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a>, because C3 fragments can accumulate on RBCs that are not destroyed by the MAC intravascularly, and these fragments opsonize the RBCs  (<a class="graphic graphic_figure graphicRef96560" href="/d/graphic/96560.html" rel="external">figure 2</a>) [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/d/html/7163.html" rel="external">"Treatment and prognosis of paroxysmal nocturnal hemoglobinuria", section on 'Eculizumab'</a>.)</p><p class="headingAnchor" id="H87618430"><span class="h2">Aplastic anemia</span><span class="headingEndMark"> — </span>Aplastic anemia (AA; pancytopenia due to hematopoietic stem cell deficiency/injury) may precede the diagnosis of PNH or, less commonly, may develop in the setting of preexisting PNH. In many cases, PNH becomes apparent after treatment of AA with immunosuppressive therapies. (See <a class="local">'Progression to pancytopenia/aplastic anemia'</a> above.)</p><p>The mechanism of PNH appearance after therapy for AA likely involves escape of PNH cells from the immune attack associated with acquired AA. Interestingly, PNH virtually never arises from inherited forms of AA [<a href="#rid59">59,60</a>]. Thus, in children and young adults, the presence of a small PNH clone in the setting of a hypocellular bone marrow virtually excludes the diagnosis of an inherited bone marrow failure disorder. (See <a class="local">'Clonal selection and expansion'</a> above.) </p><p class="headingAnchor" id="H24327595"><span class="h1">THROMBOSIS</span><span class="headingEndMark"> — </span>PNH is characterized by thrombosis in atypical locations. Venous thrombosis is significantly more common than arterial thrombosis, although instances of arterial thrombosis have been reported (eg, cerebral, coronary) [<a href="#rid61">61-65</a>]. Sites of venous thrombosis include intraabdominal vessels such as the hepatic vein (ie, Budd-Chiari syndrome); portal, mesenteric, and splenic veins; inferior vena cava; and cerebral vessels. (See  <a class="medical medical_review" href="/d/html/7159.html" rel="external">"Clinical manifestations and diagnosis of paroxysmal nocturnal hemoglobinuria", section on 'Thrombosis'</a>.)</p><p>The pathogenesis of thrombosis in PNH is multifactorial and incompletely understood; there are several hypothesized mechanisms [<a href="#rid66">66,67</a>]. A role for hemolysis in promoting thrombosis is suggested by the observation that complement inhibition reduces both hemolysis and thrombotic complications. In the absence of terminal complement inhibition, the risk of thrombosis correlates with the size of the PNH clone; however, it is not known whether this merely reflects the degree of hemolysis or other factors [<a href="#rid66">66</a>].</p><p>Specific contributing factors to the hypercoagulability in PNH may include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Free hemoglobin</strong> – Hemoglobin is released from lysed red blood cells (RBCs) during episodes of hemolysis. Free hemoglobin in the circulation scavenges nitric oxide (NO), which in turn leads to vasoconstriction. Free hemoglobin may also have direct effects on the vasculature such as endothelial cell activation, which may lead to expression of tissue factor, forming a nidus of thrombogenic factors on the vessel wall [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Procoagulant microparticles</strong> – Procoagulant microparticles may be released from platelets undergoing complement-mediated attack. These particles are analogous to the procoagulant microparticles seen in disseminated intravascular coagulation (DIC) and antiphospholipid antibody syndrome (APS); they may contain a variety of prothrombotic factors that can activate platelets.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Deficiency of anticoagulant and fibrinolytic factors</strong> – Several proteins involved in fibrinolysis (clot dissolution) are GPI-anchored; these appear to be deficient in PNH cells such as monocytes. Examples include tissue factor pathway inhibitor (TFPI), proteinase 3 (PR3), and urokinase plasminogen activator receptor (u-PAR) [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased levels of C5a</strong> – The complement component C5a, which is increased in PNH, contributes to a hypercoagulable state by generating proinflammatory and prothrombotic cytokines such as interleukin-6, interleukin-8, and tumor necrosis factor-alpha [<a href="#rid61">61,70</a>].</p><p></p><p>The reason thrombosis occurs in atypical locations rather than typical locations such as deep veins of the leg is not well understood. Relatively low flow rates in intraabdominal vessels have been postulated as a potential mechanism.</p><p>The use of anticoagulants in the management and prevention of thrombosis in PNH is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7163.html" rel="external">"Treatment and prognosis of paroxysmal nocturnal hemoglobinuria", section on 'PNH with thrombosis'</a>.)</p><p class="headingAnchor" id="H87616351"><span class="h1">SMOOTH MUSCLE DYSTONIA</span><span class="headingEndMark"> — </span>A variety of diverse symptoms in PNH are due to vasospasm caused by reduced levels of circulating nitric oxide (NO) [<a href="#rid34">34</a>]. Nitric oxide is scavenged by free hemoglobin, which is released from red blood cells (RBCs) as they hemolyze. NO acts as a vasodilator in many vascular beds; thus, reduced NO levels in PNH lead to increased vascular and smooth muscle tone. The following symptoms are a consequence of reduced NO:</p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal pain</p><p class="bulletIndent1"><span class="glyph">●</span>Erectile dysfunction</p><p class="bulletIndent1"><span class="glyph">●</span>Fatigue</p><p class="bulletIndent1"><span class="glyph">●</span>Esophageal spasm</p><p></p><p>This mechanism is further supported by the finding of similar symptoms in volunteers who were infused with intravenous free hemoglobin during early attempts to produce artificial blood, and in individuals who were treated with a NO synthase inhibitor [<a href="#rid34">34</a>]. </p><p class="headingAnchor" id="H1563368499"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117610.html" rel="external">"Society guideline links: Anticoagulation in pregnancy"</a>.)</p><p class="headingAnchor" id="H13962299"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired disorder in which hematopoietic stem cells (HSCs) and their cellular progeny have reduced or absent glycosylphosphatidylinositol (GPI)-anchored proteins on the cell surface. PNH manifests clinically as chronic and/or paroxysmal intravascular hemolysis and a propensity for thrombosis, organ dysfunction, and hypocellular or dysplastic bone marrow. A subset of patients with PNH have clinically significant aplastic anemia or myelodysplastic syndromes/neoplasms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PNH stem cell </strong>– PNH originates from an acquired mutation in the <em>PIGA</em> gene (<strong>p</strong>hosphatidyl<strong>i</strong>nositol <strong>g</strong>lycan anchor biosynthesis, class <strong>A</strong>) in a self-renewing HSC. The mutated cells undergo clonal expansion, although it is uncertain if this selective growth advantage is due to accelerated proliferation, reduced apoptosis (programmed cell death), or other mechanisms. (See <a class="local">'PNH stem cell'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GPI anchor</strong> – The PIGA protein is involved in the first step in the synthesis of the glycosylphosphatidylinositol (GPI) anchor, a glycolipid that links dozens of cell-surface proteins to the plasma membrane on hematopoietic cells, including blood group antigens, adhesion molecules, and complement regulatory proteins  (<a class="graphic graphic_figure graphicRef96559" href="/d/graphic/96559.html" rel="external">figure 1</a>). (See <a class="local">'GPI anchor'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemolysis</strong> – PNH is associated with bot intravascular and extravascular hemolysis. Complement-mediated intravascular hemolysis is largely due to the lack of the GPI-linked complement inhibitor CD59 on the surface of red blood cells (RBCs)  (<a class="graphic graphic_figure graphicRef96560" href="/d/graphic/96560.html" rel="external">figure 2</a>). Extravascular hemolysis occurs due to complement-mediated destruction of erythrocytes by reticuloendothelial macrophages in the liver and spleen; extravascular hemolysis is normally blocked by CD55. (See <a class="local">'GPI anchor'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical consequences</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anemia</strong> – Anemia in PNH is largely due to intravascular hemolysis; however, other factors may contribute, including extravascular hemolysis, bone marrow failure, and iron deficiency. (See <a class="local">'Anemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thrombosis</strong> – The pathogenesis of thrombosis in PNH is multifactorial and incompletely understood. Free hemoglobin released from RBCs scavenges nitric oxide (NO), which in turn leads to vasoconstriction and possibly endothelial cell activation and expression of tissue factor. Procoagulant microparticles may be released from platelets undergoing complement-mediated attack. Deficiency of proteins involved in fibrinolysis and increases in proinflammatory/prothrombotic cytokine levels may also contribute. (See <a class="local">'Thrombosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Others</strong> – A variety of diverse symptoms in PNH, such as abdominal pain, erectile dysfunction, fatigue, and esophageal spasm, are thought to be due to vasospasm or smooth muscle spasm caused by reduced levels of NO. (See <a class="local">'Smooth muscle dystonia'</a> above.)</p><p></p><p class="headingAnchor" id="H23381413"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges the contributions of Stanley L Schrier, MD as Section Editor on this topic, his tenure as the founding Editor-in-Chief for UpToDate in Hematology, and his dedicated and longstanding involvement with the UpToDate program.</p><p>The UpToDate editorial staff acknowledges Wendell F Rosse, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005; 106:3699.</a></li><li><a class="nounderline abstract_t">Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood 2014; 124:2804.</a></li><li><a class="nounderline abstract_t">Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993; 73:703.</a></li><li><a class="nounderline abstract_t">Bessler M, Mason P, Hillmen P, Luzzatto L. Somatic mutations and cellular selection in paroxysmal nocturnal haemoglobinuria. Lancet 1994; 343:951.</a></li><li><a class="nounderline abstract_t">Bessler M, Mason PJ, Hillmen P, et al. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J 1994; 13:110.</a></li><li><a class="nounderline abstract_t">Endo M, Ware RE, Vreeke TM, et al. Molecular basis of the heterogeneity of expression of glycosyl phosphatidylinositol anchored proteins in paroxysmal nocturnal hemoglobinuria. Blood 1996; 87:2546.</a></li><li><a class="nounderline abstract_t">Miyata T, Yamada N, Iida Y, et al. Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 1994; 330:249.</a></li><li><a class="nounderline abstract_t">Nafa K, Mason PJ, Hillmen P, et al. Mutations in the PIG-A gene causing paroxysmal nocturnal hemoglobinuria are mainly of the frameshift type. Blood 1995; 86:4650.</a></li><li><a class="nounderline abstract_t">Nagarajan S, Brodsky RA, Young NS, Medof ME. Genetic defects underlying paroxysmal nocturnal hemoglobinuria that arises out of aplastic anemia. Blood 1995; 86:4656.</a></li><li><a class="nounderline abstract_t">Ostendorf T, Nischan C, Schubert J, et al. Heterogeneous PIG-A mutations in different cell lineages in paroxysmal nocturnal hemoglobinuria. Blood 1995; 85:1640.</a></li><li><a class="nounderline abstract_t">Pramoonjago P, Wanachiwanawin W, Chinprasertsak S, et al. Somatic mutations of PIG-A in Thai patients with paroxysmal nocturnal hemoglobinuria. Blood 1995; 86:1736.</a></li><li><a class="nounderline abstract_t">Ware RE, Rosse WF, Howard TA. Mutations within the Piga gene in patients with paroxysmal nocturnal hemoglobinuria. Blood 1994; 83:2418.</a></li><li><a class="nounderline abstract_t">Nafa K, Bessler M, Castro-Malaspina H, et al. The spectrum of somatic mutations in the PIG-A gene in paroxysmal nocturnal hemoglobinuria includes large deletions and small duplications. Blood Cells Mol Dis 1998; 24:370.</a></li><li><a class="nounderline abstract_t">Araten DJ, Nafa K, Pakdeesuwan K, Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci U S A 1999; 96:5209.</a></li><li><a class="nounderline abstract_t">Hu R, Mukhina GL, Piantadosi S, et al. PIG-A mutations in normal hematopoiesis. Blood 2005; 105:3848.</a></li><li><a class="nounderline abstract_t">Pu JJ, Hu R, Mukhina GL, et al. The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells. Haematologica 2012; 97:1225.</a></li><li><a class="nounderline abstract_t">Kawagoe K, Kitamura D, Okabe M, et al. Glycosylphosphatidylinositol-anchor-deficient mice: implications for clonal dominance of mutant cells in paroxysmal nocturnal hemoglobinuria. Blood 1996; 87:3600.</a></li><li><a class="nounderline abstract_t">Nozaki M, Ohishi K, Yamada N, et al. Developmental abnormalities of glycosylphosphatidylinositol-anchor-deficient embryos revealed by Cre/loxP system. Lab Invest 1999; 79:293.</a></li><li><a class="nounderline abstract_t">Johnston JJ, Gropman AL, Sapp JC, et al. The phenotype of a germline mutation in PIGA: the gene somatically mutated in paroxysmal nocturnal hemoglobinuria. Am J Hum Genet 2012; 90:295.</a></li><li><a class="nounderline abstract_t">Belet S, Fieremans N, Yuan X, et al. Early frameshift mutation in PIGA identified in a large XLID family without neonatal lethality. Hum Mutat 2014; 35:350.</a></li><li><a class="nounderline abstract_t">Nevo Y, Ben-Zeev B, Tabib A, et al. CD59 deficiency is associated with chronic hemolysis and childhood relapsing immune-mediated polyneuropathy. Blood 2013; 121:129.</a></li><li><a class="nounderline abstract_t">Höchsmann B, Murakami Y, Osato M, et al. Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation. J Clin Invest 2019; 129:5123.</a></li><li><a class="nounderline abstract_t">Wang H, Chuhjo T, Yasue S, et al. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood 2002; 100:3897.</a></li><li><a class="nounderline abstract_t">Dingli D, Luzzatto L, Pacheco JM. Neutral evolution in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A 2008; 105:18496.</a></li><li><a class="nounderline abstract_t">Araten DJ, Luzzatto L. The mutation rate in PIG-A is normal in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood 2006; 108:734.</a></li><li><a class="nounderline abstract_t">Araten DJ, Golde DW, Zhang RH, et al. A quantitative measurement of the human somatic mutation rate. Cancer Res 2005; 65:8111.</a></li><li><a class="nounderline abstract_t">Araten DJ, Zamechek L, Halverson G. No evidence of hypermutability in red cells from patients with paroxysmal nocturnal hemoglobinuria using the XK gene. Haematologica 2014; 99:e142.</a></li><li><a class="nounderline abstract_t">Pu JJ, Brodsky RA. Paroxysmal nocturnal hemoglobinuria from bench to bedside. Clin Transl Sci 2011; 4:219.</a></li><li><a class="nounderline abstract_t">Rosse WF. Paroxysmal nocturnal hemoglobinuria as a molecular disease. Medicine (Baltimore) 1997; 76:63.</a></li><li><a class="nounderline abstract_t">Kulasekararaj AG, Brodsky RA, Hill A. Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitor. Am J Hematol 2021; 96:E232.</a></li><li><a class="nounderline abstract_t">Pu JJ, Mukhina G, Wang H, et al. Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia. Eur J Haematol 2011; 87:37.</a></li><li><a class="nounderline abstract_t">Rosse WF, Gutterman LA. The effect of iron therapy in paroxysmal nocturnal hemoglobinuria. Blood 1970; 36:559.</a></li><li><a class="nounderline abstract_t">Vellenga E, Mulder NH, Nieweg HO, de Vries-Hospers HG. Endotoxin in paroxysmal nocturnal haemoglobulinuria (PNH). Br J Haematol 1982; 50:174.</a></li><li><a class="nounderline abstract_t">Rosse WF, Hillmen P, Schreiber AD. Immune-mediated hemolytic anemia. Hematology Am Soc Hematol Educ Program 2004; :48.</a></li><li><a class="nounderline abstract_t">Davies A, Simmons DL, Hale G, et al. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 1989; 170:637.</a></li><li><a class="nounderline abstract_t">Holguin MH, Fredrick LR, Bernshaw NJ, et al. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 1989; 84:7.</a></li><li><a class="nounderline abstract_t">Rooney IA, Davies A, Griffiths D, et al. The complement-inhibiting protein, protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells. Clin Exp Immunol 1991; 83:251.</a></li><li><a class="nounderline abstract_t">Zalman LS, Wood LM, Müller-Eberhard HJ. Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci U S A 1986; 83:6975.</a></li><li><a class="nounderline abstract_t">Sugita Y, Nakano Y, Oda E, et al. Determination of carboxyl-terminal residue and disulfide bonds of MACIF (CD59), a glycosyl-phosphatidylinositol-anchored membrane protein. J Biochem 1993; 114:473.</a></li><li><a class="nounderline abstract_t">Okada N, Harada R, Okada H. Erythrocytes of patients with paroxysmal nocturnal haemoglobinuria acquire resistance to complement attack by purified 20-kD homologous restriction factor. Clin Exp Immunol 1990; 80:109.</a></li><li><a class="nounderline abstract_t">Fletcher A, Bryant JA, Gardner B, et al. New monoclonal antibodies in CD59: use for the analysis of peripheral blood cells from paroxysmal nocturnal haemoglobinuria (PNH) patients and for the quantitation of CD59 on normal and decay accelerating factor (DAF)-deficient erythrocytes. Immunology 1992; 75:507.</a></li><li><a class="nounderline abstract_t">Hall SE, Rosse WF. The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Blood 1996; 87:5332.</a></li><li><a class="nounderline abstract_t">Nilsson B, Hagström U, Englund A, Säfwenberg J. A simplified assay for the specific diagnosis of paroxysmal nocturnal hemoglobinuria: detection of DAF(CD55)- and HRF20(CD59)- erythrocytes in microtyping cards. Vox Sang 1993; 64:43.</a></li><li><a class="nounderline abstract_t">Schubert J, Alvarado M, Uciechowski P, et al. Diagnosis of paroxysmal nocturnal haemoglobinuria using immunophenotyping of peripheral blood cells. Br J Haematol 1991; 79:487.</a></li><li><a class="nounderline abstract_t">Shichishima T, Terasawa T, Hashimoto C, et al. Heterogenous expression of decay accelerating factor and CD59/membrane attack complex inhibition factor on paroxysmal nocturnal haemoglobinuria (PNH) erythrocytes. Br J Haematol 1991; 78:545.</a></li><li><a class="nounderline abstract_t">Holguin MH, Wilcox LA, Bernshaw NJ, et al. Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 1989; 84:1387.</a></li><li><a class="nounderline abstract_t">Yamashina M, Ueda E, Kinoshita T, et al. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1990; 323:1184.</a></li><li><a class="nounderline abstract_t">Holt DS, Botto M, Bygrave AE, et al. Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. Blood 2001; 98:442.</a></li><li><a class="nounderline abstract_t">Meri S, Morgan BP, Davies A, et al. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 1990; 71:1.</a></li><li><a class="nounderline abstract_t">Rollins SA, Sims PJ. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 1990; 144:3478.</a></li><li><a class="nounderline abstract_t">Rollins SA, Zhao J, Ninomiya H, Sims PJ. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J Immunol 1991; 146:2345.</a></li><li><a class="nounderline abstract_t">Nicholson-Weller A, Spicer DB, Austen KF. Deficiency of the complement regulatory protein, "decay-accelerating factor," on membranes of granulocytes, monocytes, and platelets in paroxysmal nocturnal hemoglobinuria. N Engl J Med 1985; 312:1091.</a></li><li><a class="nounderline abstract_t">Pangburn MK, Schreiber RD, Müller-Eberhard HJ. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A 1983; 80:5430.</a></li><li><a class="nounderline abstract_t">Logue GL, Rosse WF, Adams JP. Mechanisms of immune lysis of red blood cells in vitro. I. Paroxysmal nocturnal hemoglobinuria cells. J Clin Invest 1973; 52:1129.</a></li><li><a class="nounderline abstract_t">Parker CJ, Baker PJ, Rosse WF. Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 1982; 69:337.</a></li><li><a class="nounderline abstract_t">Rosse WF, Logue GL, Adams J, Crookston JH. Mechanisms of immune lysis of the red cells in hereditary erythroblastic multinuclearity with a positive acidified serum test and paroxysmal nocturnal hemoglobinuria. J Clin Invest 1974; 53:31.</a></li><li><a class="nounderline abstract_t">Nakakuma H, Nagakura S, Iwamoto N, et al. Paroxysmal nocturnal hemoglobinuria clone in bone marrow of patients with pancytopenia. Blood 1995; 85:1371.</a></li><li><a class="nounderline abstract_t">Risitano AM. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies. Adv Exp Med Biol 2013; 735:155.</a></li><li><a class="nounderline abstract_t">DeZern AE, Symons HJ, Resar LS, et al. Detection of paroxysmal nocturnal hemoglobinuria clones to exclude inherited bone marrow failure syndromes. Eur J Haematol 2014; 92:467.</a></li><li><a class="nounderline abstract_t">Shah YB, Priore SF, Li Y, et al. The predictive value of PNH clones, 6p CN-LOH, and clonal TCR gene rearrangement for aplastic anemia diagnosis. Blood Adv 2021; 5:3216.</a></li><li><a class="nounderline abstract_t">Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood 2013; 121:4985.</a></li><li><a class="nounderline abstract_t">Audebert HJ, Planck J, Eisenburg M, et al. Cerebral ischemic infarction in paroxysmal nocturnal hemoglobinuria report of 2 cases and updated review of 7 previously published patients. J Neurol 2005; 252:1379.</a></li><li><a class="nounderline abstract_t">Tejada J, Hernández-Echebarría L, Sandoval V, Mostaza JL. [Cerebral ischemia as first manifestation of paroxysmal nocturnal hemoglobinuria]. Neurologia 2007; 22:471.</a></li><li><a class="nounderline abstract_t">Ziakas PD, Poulou LS, Pomoni A. Thrombosis in paroxysmal nocturnal hemoglobinuria at a glance: a clinical review. Curr Vasc Pharmacol 2008; 6:347.</a></li><li><a class="nounderline abstract_t">von Stuckrad-Barre S, Berkefeld J, Steckel D, Sitzer M. Cerebral arterial thrombosis in paroxysmal nocturnal hemoglobinuria. J Neurol 2003; 250:756.</a></li><li><a class="nounderline abstract_t">Van Bijnen ST, Van Heerde WL, Muus P. Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria. J Thromb Haemost 2012; 10:1.</a></li><li><a class="nounderline abstract_t">L'Acqua C, Hod E. New perspectives on the thrombotic complications of haemolysis. Br J Haematol 2015; 168:175.</a></li><li><a class="nounderline abstract_t">Saadi S, Holzknecht RA, Patte CP, et al. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med 1995; 182:1807.</a></li><li><a class="nounderline abstract_t">Ploug M, Plesner T, Rønne E, et al. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. Blood 1992; 79:1447.</a></li><li><a class="nounderline abstract_t">Kourtzelis I, Markiewski MM, Doumas M, et al. Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood 2010; 116:631.</a></li></ol></div><div id="topicVersionRevision">Topic 7156 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16051736" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diagnosis and management of paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25237200" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8500164" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7909012" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Somatic mutations and cellular selection in paroxysmal nocturnal haemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8306954" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8630422" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Molecular basis of the heterogeneity of expression of glycosyl phosphatidylinositol anchored proteins in paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8272086" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8541557" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Mutations in the PIG-A gene causing paroxysmal nocturnal hemoglobinuria are mainly of the frameshift type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8541558" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Genetic defects underlying paroxysmal nocturnal hemoglobinuria that arises out of aplastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7888683" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Heterogeneous PIG-A mutations in different cell lineages in paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7655005" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Somatic mutations of PIG-A in Thai patients with paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8167330" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Mutations within the Piga gene in patients with paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10087994" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The spectrum of somatic mutations in the PIG-A gene in paroxysmal nocturnal hemoglobinuria includes large deletions and small duplications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10220445" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15687243" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : PIG-A mutations in normal hematopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315493" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8611683" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Glycosylphosphatidylinositol-anchor-deficient mice: implications for clonal dominance of mutant cells in paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10092065" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Developmental abnormalities of glycosylphosphatidylinositol-anchor-deficient embryos revealed by Cre/loxP system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22305531" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The phenotype of a germline mutation in PIGA: the gene somatically mutated in paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24357517" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Early frameshift mutation in PIGA identified in a large XLID family without neonatal lethality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23149847" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : CD59 deficiency is associated with chronic hemolysis and childhood relapsing immune-mediated polyneuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31430258" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393738" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19011109" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Neutral evolution in paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16543465" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The mutation rate in PIG-A is normal in patients with paroxysmal nocturnal hemoglobinuria (PNH).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16166284" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A quantitative measurement of the human somatic mutation rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24816235" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : No evidence of hypermutability in red cells from patients with paroxysmal nocturnal hemoglobinuria using the XK gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21707954" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Paroxysmal nocturnal hemoglobinuria from bench to bedside.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9100736" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Paroxysmal nocturnal hemoglobinuria as a molecular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33780028" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21447004" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5473516" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The effect of iron therapy in paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7055534" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Endotoxin in paroxysmal nocturnal haemoglobulinuria (PNH)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15561676" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Immune-mediated hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2475570" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2738160" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1704296" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The complement-inhibiting protein, protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2428045" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8276756" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Determination of carboxyl-terminal residue and disulfide bonds of MACIF (CD59), a glycosyl-phosphatidylinositol-anchored membrane protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1691059" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Erythrocytes of patients with paroxysmal nocturnal haemoglobinuria acquire resistance to complement attack by purified 20-kD homologous restriction factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1374058" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : New monoclonal antibodies in CD59: use for the analysis of peripheral blood cells from paroxysmal nocturnal haemoglobinuria (PNH) patients and for the quantitation of CD59 on normal and decay accelerating factor (DAF)-deficient erythrocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8652849" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7680511" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A simplified assay for the specific diagnosis of paroxysmal nocturnal hemoglobinuria: detection of DAF(CD55)- and HRF20(CD59)- erythrocytes in microtyping cards.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1751377" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Diagnosis of paroxysmal nocturnal haemoglobinuria using immunophenotyping of peripheral blood cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1716957" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Heterogenous expression of decay accelerating factor and CD59/membrane attack complex inhibition factor on paroxysmal nocturnal haemoglobinuria (PNH) erythrocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2478585" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1699124" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11435315" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1698710" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1691760" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1706395" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3845321" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Deficiency of the complement regulatory protein, "decay-accelerating factor," on membranes of granulocytes, monocytes, and platelets in paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6225118" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4700488" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Mechanisms of immune lysis of red blood cells in vitro. I. Paroxysmal nocturnal hemoglobinuria cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6915939" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4855546" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Mechanisms of immune lysis of the red cells in hereditary erythroblastic multinuclearity with a positive acidified serum test and paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7532041" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Paroxysmal nocturnal hemoglobinuria clone in bone marrow of patients with pancytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23402025" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24612308" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Detection of paroxysmal nocturnal hemoglobinuria clones to exclude inherited bone marrow failure syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34427585" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The predictive value of PNH clones, 6p CN-LOH, and clonal TCR gene rearrangement for aplastic anemia diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23610373" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Thrombosis in paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16021362" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cerebral ischemic infarction in paroxysmal nocturnal hemoglobinuria report of 2 cases and updated review of 7 previously published patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17853967" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : [Cerebral ischemia as first manifestation of paroxysmal nocturnal hemoglobinuria].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18855722" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Thrombosis in paroxysmal nocturnal hemoglobinuria at a glance: a clinical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12862033" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cerebral arterial thrombosis in paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22077430" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25307023" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : New perspectives on the thrombotic complications of haemolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7500026" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Complement-mediated regulation of tissue factor activity in endothelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1312369" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20424189" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
